MRK · Merck & Co., Inc. · Webcasts, Transcripts & Audio
$148.36
-1.16 (-0.78%)
At close · Nov 2
Return incl. dividend (before tax)
Q2 2026 earnings call transcript
Market Cap
$368.89B
Shares
2.47B
Volume · Nov 2
9.1M
Avg daily vol (3M)
10.35M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Merck & Co., Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Merck & Co., Inc. (MRK), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Earnings call
FY27 · Q3
2027-10-28
Merck & Co., Inc. (MRK) Q3 2027 Earnings Call
Scheduled
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY27 · Q2
2027-08-03
Merck & Co., Inc. (MRK) Q2 2027 Earnings Call
Scheduled
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY27 · Q1
2027-04-29
Merck & Co., Inc. (MRK) Q1 2027 Earnings Call
Scheduled
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q4
2027-02-02
Merck & Co., Inc. (MRK) Q4 2026 Earnings Call
Scheduled
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY26 · Q3
2026-10-29
Merck & Co., Inc. (MRK) Q3 2026 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Investor Update
Investor event
2026-10-26
Merck & Co., Inc. (MRK) October 26, 2026 Investor Update
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-09-14
Merck & Co., Inc. (MRK) September 14, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-09-09
Merck & Co., Inc. (MRK) September 9, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-09-09
Merck & Co., Inc. (MRK) September 9, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-04
Merck & Co., Inc. (MRK) Q2 2026 Earnings Call Transcript
Confident tone
Keytruda oncology franchise
PD-1 VEGF bispecific and TL1A strategy
Lipfendra oral PCSK9 launch
Revenue
$16.61B
▲ 5.1% YoY Diluted EPS
$-0.54
▼ 130.7% YoY Gross margin
73.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-08-03
Merck & Co., Inc. (MRK) August 3, 2026 Conference
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-06-09
Merck & Co., Inc. (MRK) June 9, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-06-04
Merck & Co., Inc. (MRK) June 4, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Investor Update
Investor event
2026-06-01
Merck & Co., Inc. (MRK) June 1, 2026 Investor Update
No reported result — non-financial event
Audio
Transcript
Slides
Annual General Meeting
Investor event
2026-05-26
Merck & Co., Inc. (MRK) May 26, 2026 Annual General Meeting Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-04-30
Merck & Co., Inc. (MRK) Q1 2026 Earnings Call Transcript
Confident tone
Oncology / KEYTRUDA
Pipeline and Phase III catalysts
Terns Pharmaceuticals / TERN-701 (CML)
Revenue
$16.29B
▲ 4.9% YoY Diluted EPS
$-1.72
▼ 185.6% YoY Gross margin
74.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-03
Merck & Co., Inc. (MRK) Q4 2025 Earnings Call Transcript
Confident tone
Long-term commercial opportunity / pipeline transformation
Business development and M&A
Ophthalmology / MK-3000
Revenue
$16.40B*
▲ 5% YoY Gross margin
66.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Conference
Investor event
2026-01-12
Merck & Co., Inc. (MRK) January 12, 2026 Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q3
2025-10-30
Merck & Co., Inc. (MRK) Q3 2025 Earnings Call Transcript
Positive tone
Pipeline and R&D progress
Keytruda franchise and QLEX launch
WINREVAIR and new product launches
Revenue
$17.28B
▲ 3.7% YoY Diluted EPS
$2.32
▲ 87.1% YoY Gross margin
77.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-07-29
Merck & Co., Inc. (MRK) Q2 2025 Earnings Call Transcript
Confident tone
Pipeline and R&D momentum
New product launches (WINREVAIR, CAPVAXIVE, ENFLONSIA)
Business development / Verona Pharma acquisition
Revenue
$15.81B
▼ 1.9% YoY Diluted EPS
$1.76
▼ 17.8% YoY Gross margin
77.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-04-24
Merck & Co., Inc. (MRK) Q1 2025 Earnings Call Transcript
Positive tone
GARDASIL China decline
Tariffs and global supply chain
BD strategy characterization
Revenue
$15.53B
▼ 1.6% YoY Diluted EPS
$2.01
▲ 7.5% YoY Gross margin
78.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-04
Merck & Co., Inc. (MRK) Q4 2024 Earnings Call Transcript
Positive tone
GARDASIL China headwind
WINREVAIR launch and PAH opportunity
KEYTRUDA and oncology franchise
Revenue
$15.62B*
▲ 6.8% YoY Gross margin
75.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-10-31
Merck & Co., Inc. (MRK) Q3 2024 Earnings Call Transcript
Positive tone
GARDASIL China headwinds and inventory
KEYTRUDA oncology leadership
Vaccines pipeline (clesrovimab and others)
Revenue
$16.66B
▲ 4.4% YoY Diluted EPS
$1.24
▼ 33.3% YoY Gross margin
75.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-07-30
Merck & Co., Inc. (MRK) Q2 2024 Earnings Call Transcript
Confident tone
GARDASIL / HPV
WINREVAIR launch
Pipeline breadth and BD
Revenue
$16.11B
▲ 7.2% YoY Diluted EPS
$2.14
Gross margin
76.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-04-25
Merck & Co., Inc. (MRK) Q1 2024 Earnings Call Transcript
Confident tone
Vaccines pipeline (HPV, pneumococcal)
KEYTRUDA growth
WINREVAIR launch (PAH)
Revenue
$15.78B
▲ 8.9% YoY Diluted EPS
$1.87
▲ 68.5% YoY Gross margin
77.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-01
Merck & Co., Inc. (MRK) Q4 2023 Earnings Call Transcript
Confident tone
Pipeline diversification and late-stage catalysts
Vaccines portfolio including RSV and dengue
Keytruda momentum and oncology leadership
Revenue
$14.63B*
▲ 5.8% YoY Gross margin
73.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-10-26
Merck & Co., Inc. (MRK) Q3 2023 Earnings Call Transcript
Revenue
$15.96B
▲ 6.7% YoY Diluted EPS
$1.86
▲ 45.3% YoY Gross margin
73.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-01
Merck & Co., Inc. (MRK) Q2 2023 Earnings Call Transcript
Revenue
$15.04B
▲ 3% YoY Diluted EPS
$-2.35
▼ 251.6% YoY Gross margin
73.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-04-27
Merck & Co., Inc. (MRK) Q1 2023 Earnings Call Transcript
Revenue
$14.49B
▼ 8.9% YoY Diluted EPS
$1.11
▼ 34.7% YoY Gross margin
72.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-02
Merck & Co., Inc. (MRK) Q4 2022 Earnings Call Transcript
Revenue
$13.83B*
▲ 2.3% YoY Gross margin
71.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-10-27
Merck & Co., Inc. (MRK) Q3 2022 Earnings Call Transcript
Revenue
$14.96B
▲ 13.7% YoY Diluted EPS
$1.28
▼ 28.9% YoY Gross margin
73.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-07-28
Merck & Co., Inc. (MRK) Q2 2022 Earnings Call Transcript
Revenue
$14.59B
▲ 28% YoY Diluted EPS
$1.55
▲ 154.1% YoY Gross margin
71.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-04-28
Merck & Co., Inc. (MRK) Q1 2022 Earnings Call Transcript
Revenue
$15.90B
▲ 49.6% YoY Diluted EPS
$1.70
▲ 36% YoY Gross margin
66.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-03
Merck & Co., Inc. (MRK) Q4 2021 Earnings Call Transcript
Revenue
$13.52B*
▲ 47.3% YoY Gross margin
71.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-10-28
Merck & Co., Inc. (MRK) Q3 2021 Earnings Call Transcript
Revenue
$13.15B
▲ 20.4% YoY Diluted EPS
$1.80
▲ 55.2% YoY Gross margin
73.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-07-29
Merck & Co., Inc. (MRK) Q2 2021 Earnings Call Transcript
Revenue
$11.40B
▲ 21.9% YoY Diluted EPS
$0.61
▼ 48.3% YoY Gross margin
72.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-04-29
Merck & Co., Inc. (MRK) Q1 2021 Earnings Call Transcript
Revenue
$10.63B
▼ 11.9% YoY Diluted EPS
$1.25
▼ 0.8% YoY Gross margin
69.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-04
Merck & Co., Inc. (MRK) Q4 2020 Earnings Call Transcript
Revenue
$9.18B*
▲ 121.3% YoY Gross margin
50.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-10-27
Merck & Co., Inc. (MRK) Q3 2020 Earnings Call Transcript
Revenue
$10.93B
▼ 11.8% YoY Diluted EPS
$1.16
▲ 56.8% YoY Gross margin
72.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-07-31
Merck & Co., Inc. (MRK) Q2 2020 Earnings Call Transcript
Revenue
$9.35B
▼ 20.5% YoY Diluted EPS
$1.18
▲ 14.6% YoY Gross margin
70.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-04-28
Merck & Co., Inc. (MRK) Q1 2020 Earnings Call Transcript
Revenue
$12.06B
▲ 11.5% YoY Diluted EPS
$1.26
▲ 12.5% YoY Gross margin
72.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-02-05
Merck & Co., Inc. (MRK) Q4 2019 Earnings Call
Revenue
$4.15B*
▼ 62.3% YoY Gross margin
62.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–42 of 42 webcasts
Key facts
CIK
310158
CUSIP
58933Y105
13F (30d)
1970 filings
1901 filers
Visit website
Investor relations